Hence, all therapeutic targets that could halt IL-17A production and IL-17-dependent retinal pathogenesis could be a potential therapeutic that could enhance the efficacy of anti-VEGF treatment, and delay the onset of diabetic retinopathy. Here, IL17A is linked to diabetic retinopathy.